Neoadjuvant Interferons: Critical for Effective PD-1-Based Immunotherapy in TNBC

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• Triple-negative breast cancer (TNBC) lacks targeted therapies for patients unresponsive to chemotherapy.
• Current immunotherapies targeting the PD-1/PD-L1 axis show limited efficacy in TNBC.
• Understanding the interplay between type I IFN signaling and PD-1/PD-L1 is crucial for developing effective treatments.

Purpose of the Study:

• To investigate the interaction between type I IFN signaling and the PD-1/PD-L1 axis in TNBC.
• To evaluate the efficacy of combining IFN inducers with anti-PD-1 therapy for antimetastatic immune response.
• To determine the optimal timing for combination immunotherapy in TNBC models.

Main Methods:

• Utilized preclinical models of triple-negative breast cancer.
• Administered type I IFN inducer poly(I:C) and anti-PD-1, both as single agents and in combination.
• Assessed therapeutic response, PD-L1 expression, immune activation, and metastasis-free survival.

Main Results:

• Type I IFN signaling influences tumor cell PD-L1 expression and therapeutic response.
• Poly(I:C) effectively activated the immune system and demonstrated antimetastatic properties, outperforming anti-PD-1 alone.
• Combination therapy with poly(I:C) and anti-PD-1 in the neoadjuvant setting significantly prolonged metastasis-free survival by inducing a tumor-specific T-cell response.

Conclusions:

• Anti-PD-1 is ineffective as a monotherapy in preclinical TNBC models.
• Type I IFN inducers are potent immune activators with antimetastatic potential.
• Neoadjuvant combination therapy of type I IFN inducers and anti-PD-1 warrants further investigation for sustained anti-tumor immunity in TNBC.